Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of BT200 (Rondoraptivon Pegol) in Patients With Type 2B Von Willebrand Disease

NCT07273721 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT07273721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07273721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of BT200 (Rondoraptivon Pegol) in Patients With Type 2B Von Willebrand Disease
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Recruiting
Start date
August 14, 2025
Completion date
July 31, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease (vwd), type 2